ONCR dividend history

Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

To report initial data from ongoing Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate, ONCR-177, in multiple solid tumor indications at the upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting on November 12thCompleted Pre-IND meeting and initiating GLP IND-enabling safety and tolerability studies for lead intravenously (IV) administered Synthetic viral RNA (vRNA) immunotherapy candidate, ONCR-021 (Synthetic CVA21); plans to submit an IND for ONCR-021 in the first half of 2023Continues non-GLP safety and tolerability studies for second Synthetic vRNA immunotherapy candidate ONCR-788 (Synthetic SVV)First phase of GMP clinic

Continues to progress Phase 1 clinical trial of ONCR-177, company's lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate; on track to report initial interim data in 4Q'21Nominated company's first intravenously (IV) administered Synthetic viral RNA (vRNA) immunotherapy candidates, ONCR-021 (Synthetic CVA21) and ONCR-788 (Synthetic SVV)Anticipates first phase of GMP clinical manufacturing facility, including process development and quality control, to be completed in 2021, as previously guidedExpanded Board of Directors with appointments of Eric H. Rubin, M.D., and Barbara Yanni$159.9 million in cash and cash equivalents as of June 30, 2021 CAMBRIDGE, Mass., Aug. 04, 2021